For the Inventor, By the Inventor

Enter assignee name

Seongnam-si, South Korea

Genexine, Inc.

USPTO Granted Patents = 24

CIPO Patents = 1

EPO Patents = 10

Trademarks = 8

Forward Citations = 48

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

Young Chul Sung (14 out of 24 patents)

Donghoon Choi (8 out of 8 patents)

Se Hwan Yang (5 out of 5 patents)

4. Hye Seong Lim (4 out of 4 patents)

5. Sehwan Yang (4 out of 5 patents)

6. Moon Cheol Kang (3 out of 3 patents)

7. Young Woo Choi (3 out of 3 patents)

8. You Suk Suh (3 out of 4 patents)

9. Sang Hwan Seo (3 out of 4 patents)

10. Woo Ick Jang (3 out of 3 patents)

11. Jung Won Woo (3 out of 3 patents)

12. Changyong Eun (2 out of 2 patents)

13. Jun Yeul Lim (2 out of 2 patents)

14. Tae Kyung Kim (2 out of 54 patents)

15. Seong Hoon Jeong (2 out of 3 patents)

24 patents: Sort by Forward Citations

1. 12479898 - PHARMACEUTICAL COMPOSITION COMPRISING IMMUNOGLOBULIN FC-FUSED INTERLEUKIN-7 FUSION PROTEIN FOR PREVENTING OR TREATING HUMAN PAPILLOMAVIRUS-CAUSED DISEASES (2025-11-25),

2. 12427186 - Method for treating growth hormone deficiency employing hGH fusion protein (2025-09-30),

3. 12357677 - Virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein (2025-07-15),

4. 12344647 - Formulation of modified interleukin-7 fusion protein (2025-07-01),

5. 12233113 - Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency (2025-02-25),

6. 11883479 - Method for treating cervical cancer (2024-01-30),

7. 11708399 - Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases (2023-07-25),

8. 11548927 - Formulation of modified interleukin-7 fusion protein (2023-01-10),

9. 11524054 - Method of treating anemia using long-acting EPO formulation (2022-12-13),

10. 11357827 - Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein (2022-06-14),

11. 11135262 - Methods of treating cervical cancer (2021-10-05),

12. 11041007 - Modified interleukin-7 protein (2021-06-22),

13. 10844104 - Modified interleukin-7 protein (2020-11-24),

14. 10538569 - Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof (2020-01-21),

15. 10208099 - Modified interleukin-7 protein (2019-02-19),

Genexine, Inc. is a biotechnology company specializing in the development of innovative immunotherapeutics and next-generation vaccines. With a focus on genetic engineering, their proprietary technologies have enabled the development of various product candidates for the treatment of cancer, infectious diseases, and autoimmune disorders. Genexine's mission is to improve patients' lives by providing effective and safe therapeutic solutions through continuous innovation and clinical research.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

24 Patents

#25 in Seongnam-si

#529 in South Korea

#25,881 in the World

Seongnam-si, South Korea

Genexine, Inc.

Forward Citations = 48

47 inventors:

Young Chul Sung (14 out of 24 patents)

Donghoon Choi (8 out of 8 patents)

Se Hwan Yang (5 out of 5 patents)

4. Hye Seong Lim (4 out of 4 patents)

5. Sehwan Yang (4 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…